Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)07:02

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)

13.0K
Host cell factors play a critical role in the establishment and maintenance of Kaposi's sarcoma (KS). We outline methods to identify host cell factors altered in KSHV-infected DMVEC cells, and in KS tumor tissue. Cellular genes altered by virus will serve as potential target(s) for novel...
13.0K
An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus09:53

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

9.3K
Kaposi sarcoma (KS) is a tumor induced by infection with the oncogenic virus human herpesvirus-8/KS herpesvirus (HHV-8/KSHV). The endothelial cell culture model described here is uniquely suited for studying the mechanisms by which KSHV transforms host cells.
9.3K
Establishment and Quantification of De Novo Lytic Infection by Cell-free Kaposi's Sarcoma-Associated Herpesvirus07:10

Establishment and Quantification of De Novo Lytic Infection by Cell-free Kaposi's Sarcoma-Associated Herpesvirus

806
This protocol describes an in vitro system to model de novo lytic infection of Kaposi's sarcoma-associated herpesvirus using BAC16-derived virions. The method enables investigation of early viral replication and dissemination. Infectious virus production is quantified by GFP-based infectious units assays and real-time PCR of encapsidated viral...
806
The In ovo CAM-assay as a Xenograft Model for Sarcoma12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

26.2K
The in ovo chorioallantoic membrane (CAM) is grafted with fresh sarcoma-derived tumor tissues, their single cell suspensions, and permanent and transient fluorescently labeled established sarcoma cell lines. The model is used to study graft- (viability, Ki67 proliferation index, necrosis, infiltration) and host (fibroblast infiltration, vascular ingrowth)...
26.2K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

9.8K
We present here a cell culture method for inducing mesenchymal-epithelial transitions (MET) in sarcoma cells based on combined ectopic expression of microRNA-200 family members and grainyhead-like 2 (GRHL2). This method is suitable for better understanding the biological impact of phenotypic plasticity on cancer aggressiveness and...
9.8K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

14.9K
The following protocol focuses on the establishment of a primary culture of patient-derived soft tissue sarcoma (STS). This model could help us to better understand the molecular background and pharmacological profile of these rare malignancies and could represent a starting point for further research aimed at improving STS...
14.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leukemia cutis and all-trans retinoic acid-induced myocarditis in acute promyelocytic leukemia.

Clinical hematology international·2026
Same author

Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors.

JAMA dermatology·2025
Same author

Single-cell immunopathology of recurrent acute generalized exanthematous pustulosis associated with vancomycin.

The journal of allergy and clinical immunology. Global·2025
Same author

Enhanced Recovery After Gender-Affirming Surgery.

Aesthetic surgery journal·2024
Same author

Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.

Journal for immunotherapy of cancer·2024
Same author

Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade Using Tissue Cyclic Immunofluorescence: A Pilot Study.

The Journal of investigative dermatology·2024
Same journal

The Evidence Is In: Devices and Biologics Reshaping Modern Dermatology.

Dermatologic clinics·2026
Same journal

Energy-Based Devices for Body Contouring.

Dermatologic clinics·2026
Same journal

Microfocused Ultrasound with Visualization for Skin Tightening: Clinical Applications, Safety, and Technical Considerations.

Dermatologic clinics·2026
Same journal

Devices in Onychomycosis: A Status Update.

Dermatologic clinics·2026
Same journal

Acne Laser Devices in Dermatology.

Dermatologic clinics·2026
Same journal

Fractional Laser Therapy for Androgenetic Alopecia: Mechanisms, Clinical Evidence, and Practical Implementation.

Dermatologic clinics·2026
See all related articles

Related Experiment Video

Updated: Jan 20, 2026

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV
07:02

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV

Published on: September 14, 2010

13.0K

Kaposi Sarcoma Updates.

Shervin A Etemad1, Anna K Dewan1

  • 1Department of Dermatology, Vanderbilt University Medical Center, 719 Thompson Lane, One Hundred Oaks, Suite 26300, Nashville, TN 37204, USA.

Dermatologic Clinics
|August 31, 2019
PubMed
Summary
This summary is machine-generated.

Kaposi sarcoma (KS), a herpesvirus-caused cancer, is better understood post-antiretroviral therapy. New treatments like checkpoint inhibitors offer future hope for KS patients.

Keywords:
AIDSHHV8HIVImmunosuppressionKaposi sarcomaSarcoma

More Related Videos

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus
09:53

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

Published on: August 25, 2017

9.3K
Establishment and Quantification of De Novo Lytic Infection by Cell-free Kaposi's Sarcoma-Associated Herpesvirus
07:10

Establishment and Quantification of De Novo Lytic Infection by Cell-free Kaposi's Sarcoma-Associated Herpesvirus

Published on: August 15, 2025

806

Related Experiment Videos

Last Updated: Jan 20, 2026

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV
07:02

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV

Published on: September 14, 2010

13.0K
An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus
09:53

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

Published on: August 25, 2017

9.3K
Establishment and Quantification of De Novo Lytic Infection by Cell-free Kaposi's Sarcoma-Associated Herpesvirus
07:10

Establishment and Quantification of De Novo Lytic Infection by Cell-free Kaposi's Sarcoma-Associated Herpesvirus

Published on: August 15, 2025

806

Area of Science:

  • Oncology
  • Virology
  • Epidemiology

Background:

  • Kaposi sarcoma (KS) is a mesenchymal neoplasm linked to Kaposi sarcoma-related herpesvirus.
  • Understanding KS epidemiology is crucial, especially in the context of antiretroviral therapy and endemic African subtypes.

Purpose of the Study:

  • To review current knowledge on Kaposi sarcoma epidemiology, pathogenesis, clinical presentation, and staging.
  • To highlight recent advancements and future directions in KS treatment.

Main Methods:

  • Literature review of recent research on Kaposi sarcoma.
  • Analysis of epidemiological data in the post-antiretroviral therapy era.
  • Examination of emerging clinical oncology and skin-directed therapies.

Main Results:

  • Updated understanding of KS epidemiology, particularly concerning the African endemic subtype.
  • Identification of new therapeutic strategies, including checkpoint inhibitors and novel skin-directed treatments.
  • Recognition of the evolving landscape of KS management.

Conclusions:

  • Continued research is needed to fully characterize the African endemic subtype of KS.
  • Advances in oncology offer promising new treatment avenues for Kaposi sarcoma.
  • A comprehensive understanding of KS epidemiology and pathogenesis informs clinical management and therapeutic development.